Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets

Keskin M., Savas-Erdeve S., Sagsak E., Cetinkaya S., AYCAN Z.

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.28, sa.11-12, ss.1333-1337, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 11-12
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1515/jpem-2014-0447
  • Dergi Adı: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1333-1337
  • Anahtar Kelimeler: bone deformity, calcium, hypophosphatemic rickets, nephrocalcinosis, X-LINKED HYPOPHOSPHATEMIA, CHILDREN, PHOSPHATE, GROWTH, THERAPY
  • Ankara Üniversitesi Adresli: Hayır

Özet

The aim of the present study was to analyse the effects of combined treatment with calcitriol and phosphate, to find out the incidence of the nephrocalcinosis, and to elucidate the risk factor of nephrocalcinosis in patients with hypophosphatemic rickets. We followed six patients. The median age at diagnosis was 3.25 (0.75-10.5) years. The median follow-up duration was 8.25 (3.5-12.5) years. The mean dose of calcitriol and phosphate treatments was 39.1 +/- 8 ng/kg/day, 90.5 +/- 57.1 mg/kg/day, respectively. Nephrocalcinosis was detected in three patients (50%). The mean dose of phosphate taken by the patients found to have nephrocalcinosis was detected to be high with a statistically significant difference (p=0.041). No significant relationship was found the mean dose of calcitriol. We found no relationship between the development of nephrocalcinosis and the incidence of hypercalciuria or hypercalcemia episodes. We found the increased phosphate dose administered for treatment to play a role in nephrocalcinosis development.